TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Amur Minerals ( (GB:CRTX) ) has issued an announcement.
CRISM Therapeutics Corporation has announced significant progress in the development of its ChemoSeed technology, particularly for the treatment of glioblastoma, an aggressive form of brain cancer. The company has received approval for its Clinical Trial Application for a Phase 2 trial and has initiated the manufacturing of clinical batches, with patient recruitment expected to begin in early 2026. Additionally, CRISM has made strides in its prostate cancer program and secured funding to support further development, positioning itself as a key player in addressing unmet medical needs in cancer treatment.
More about Amur Minerals
CRISM Therapeutics Corporation is a UK-based clinical-stage pharmaceutical company specializing in innovative drug delivery technology. The company focuses on the localized and sustained delivery of chemotherapy drugs, particularly through its proprietary ChemoSeed technology, which aims to improve the clinical performance of cancer treatments for solid tumors. CRISM’s primary market focus is on brain tumors, with plans to expand into other solid tumors such as prostate, pancreatic, and bladder cancers.
Average Trading Volume: 63,641
Technical Sentiment Signal: Sell
Current Market Cap: £3.35M
For a thorough assessment of CRTX stock, go to TipRanks’ Stock Analysis page.